Cocrystal Pharma (COCP) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month price targets for Cocrystal Pharma's shares. Their COCP share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 431.0% from the stock's current price.
View analysts price targets for COCP or view top-rated stocks among Wall Street analysts.

Cocrystal Pharma's stock was trading at $1.95 at the start of the year. Since then, COCP stock has increased by 15.9% and is now trading at $2.26.
View the best growth stocks for 2023 here.

Cocrystal Pharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 34,100 shares, a decrease of 13.7% from the April 30th total of 39,500 shares. Based on an average daily trading volume, of 70,200 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.5% of the shares of the company are short sold.
View Cocrystal Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our COCP earnings forecast.

Cocrystal Pharma, Inc. (NASDAQ:COCP) posted its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.17.

Shares of Cocrystal Pharma reverse split before market open on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP."

Cocrystal Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.18%), Sabby Management LLC (0.65%) and Susquehanna International Group LLP (0.20%). Insiders that own company stock include Phillip Md Et Al Frost, Raymond F Schinazi and Richard C Pfenniger, Jr.
View institutional ownership trends.

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COCP stock can currently be purchased for approximately $2.26.

Cocrystal Pharma (NASDAQ:COCP) has a market capitalization of $22.98 million and generates $2.01 million in revenue each year. The company earns $-38,840,000.00 in net income (profit) each year or ($4.8912) on an earnings per share basis.

Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The official website for the company is www.cocrystalpharma.com. The company can be reached via phone at (305) 425-1780 or via email at cocp@jtcir.com.